Incidence of prostate cancer in transgender women in the US: a large database analysis.
Matthew LoriaDavid GilbertTomasz TabernackiMart Andrew MaravillasMegan McNamaraShubham GuptaKirtishri MishraPublished in: Prostate cancer and prostatic diseases (2024)
The risk of prostate cancer among transgender women undergoing medical and surgical gender-affirming interventions remains unclear, though up to a fivefold decreased risk has been reported in comparison to cisgender men. In this study, we conducted a comparative analysis of the risk of prostate cancer among transgender women (TW) using data from TriNetX, a large database, versus SEER. Our findings indicate that, overall, transgender women exhibited a 2.56-fold lower risk of prostate cancer compared to cisgender men. Specifically, among TW on hormone therapy between ages 50-64, we observed a 2.06-fold decrease in risk. Contrary to the previous perception of prostate cancer being rare in transgender women, our study suggests that it may not be as uncommon as previously believed.
Keyphrases
- prostate cancer
- polycystic ovary syndrome
- radical prostatectomy
- pregnancy outcomes
- cervical cancer screening
- breast cancer risk
- hiv testing
- healthcare
- emergency department
- insulin resistance
- type diabetes
- stem cells
- mesenchymal stem cells
- adipose tissue
- skeletal muscle
- machine learning
- bone marrow
- men who have sex with men
- artificial intelligence
- adverse drug
- data analysis
- hiv infected